Alkermes Participates in President’s Commission Meeting on Combating Drug Addiction and the Opioid Crisis
September 28 2017 - 4:00PM
Business Wire
Alkermes plc (NASDAQ: ALKS) participated in the Third Meeting of
the President’s Commission on Combating Drug Addiction and the
Opioid Crisis held yesterday in Washington, D.C. The Commission was
formed to study the scope and effectiveness of the Federal response
to drug addiction and the opioid crisis and to make recommendations
to the President for improving that response. Alkermes CEO Richard
Pops joined government, nonprofit, and business organizations at
yesterday’s meeting to testify in support of the Commission’s
ongoing effort to discuss innovative solutions to address the
opioid crisis. The purpose of yesterday’s meeting was to review
education efforts, treatment options and measures to prevent
diversion.
“Alkermes is honored to be included in this important national
dialogue. We are encouraged by the level of engagement by senior
policymakers and public health officials to evaluate the treatment
status quo and consider new treatment approaches to help address
the opioid epidemic,” said Richard Pops, Chief Executive Officer of
Alkermes. “At a moment when healthcare accessibility and
affordability are in the spotlight of our national dialogue,
Alkermes is providing patient-centered treatment options to those
afflicted by addiction and serious mental illness. We have been
committed to these patients for many years, and are proud to be
working with healthcare providers, public health officials and
policymakers to address these devastating diseases that wreak havoc
on patients, their families and in our communities.”
Please click here to read a corporate statement on the
testimony.
About Opioid DependenceA
chronic brain disease, opioid dependence is characterized by
cognitive, behavioral and physiological symptoms in which an
individual continues to use opioids despite significant harm to
oneself and others.1 The use of heroin, an illegal opioid drug, and
the non-medical use of FDA-approved opioid analgesics, including
prescription pain relievers, represents a growing public health
problem in the U.S. According to the 2014 U.S. National Survey on
Drug Use and Health, an estimated 2.3 million people aged 18 or
older were dependent on pain relievers or heroin in the U.S.2
About AlkermesAlkermes
plc is a fully integrated, global biopharmaceutical company
developing innovative medicines for the treatment of central
nervous system (CNS) diseases. The company has a diversified
commercial product portfolio and a substantial clinical pipeline of
product candidates for chronic diseases that include schizophrenia,
depression, addiction and multiple sclerosis. Headquartered in
Dublin, Ireland, Alkermes plc has an R&D center in Waltham,
Massachusetts; a research and manufacturing facility in Athlone,
Ireland; and a manufacturing facility in Wilmington, Ohio. For more
information, please visit Alkermes’ website
at www.alkermes.com.
1 DSM-IV-TR, American Psychiatric Association.
2 SAMHSA. Behavioral Health Trends in the United States: Results
from the 2014 National Survey on Drug Use and Health. Accessed on
Sept. 28, 2017 from
http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170928006310/en/
Alkermes plcFor Investors:Sandy Coombs, +1 781-609-6377orEva
Stroynowski, +1 781-609-6823orFor Media:Jennifer Snyder, +1 781
609-6166
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Sep 2023 to Sep 2024